Analyst Gil Blum from Needham maintained a Buy rating on Celcuity and keeping the price target at $95.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Gil Blum has given his Buy rating due to a combination of factors related to Celcuity’s recent developments and financial position. The company has initiated the NDA filing for gedatolisib in PIK3CA wild-type metastatic breast cancer, utilizing the real-time oncology review program, with expectations to complete the submission by the end of 2025. This strategic move is supported by the completion of enrollment in the PIK3CA mutant cohort of the Phase III VIKTORIA-1 study, with a significant readout anticipated in early 2026.
Additionally, Celcuity’s strong financial standing, bolstered by recent equity and debt financing, provides a robust cash reserve of $455 million. This capital is projected to sustain operations through 2027, positioning the company well for the commercial launch of gedatolisib. These elements collectively underpin the Buy rating, reflecting confidence in the company’s strategic direction and financial health.
Blum covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Celcuity, and Autolus Therapeutics. According to TipRanks, Blum has an average return of 4.7% and a 39.76% success rate on recommended stocks.